Granted Patent
B2
US 12,433,957 · App. 18/893,280 · Granted Oct 7, 2025
Compositions and methods for delivery of RNA
Inventors:
Amit Khandhar (Issaquah, WA); Steven Reed (Bellevue, WA); Malcolm Duthie (Sammamish, WA); Jesse Erasmus (Port Orchard, WA); Darrick Carter (Seattle, WA); Bryan J. Berube (Issaquah, WA)
Assignee:
HDT Bio Corp.
A61K47/6907A61K9/1075A61K9/127A61K9/5115A61K9/5123A61K31/7105A61K31/711A61K31/713A61K39/215A61K39/39A61K47/02A61K47/44A61K47/6911A61K47/6923A61K49/183A61K49/1833A61P31/14C07K14/165C12N15/86C12N15/88A61K2039/55555A61K47/10A61K47/26A61K47/547B82Y5/00B82Y25/00B82Y30/00B82Y40/00C12N2770/36143
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.
Claims (26)
1. A composition, wherein the composition comprises:
lipid nanoparticles, wherein the lipid nanoparticles are characterized as having a z-average diameter particle size measurement of 20 nm to about 60 nm when measured using dynamic light scattering, and wherein the lipid nanoparticles comprise:
a surface comprising cationic lipids; and
a hydrophobic core that comprises liquid oil, wherein lipids present in the hydrophobic core are in liquid phase at 25 degrees Celsius,
at least one nucleic acid, wherein the at least one nucleic acid comprises a sequence encoding for an RNA-dependent polymerase and a non-coding RNA.
2. The composition of claim 1 , wherein the non-coding RNA comprises a microRNA.
3. The composition of claim 1 , wherein the non-coding RNA comprises a silencing RNA.
4. The composition of claim 1 , wherein the RNA-dependent polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase.
5. The composition of claim 1 , wherein the at least one nucleic acid further comprises a sequence encoding for a protein antigen.
6. The composition of claim 5 , wherein the protein antigen is derived from a virus.
7. The composition of claim 5 , wherein the protein antigen is derived from a cancer.
8. The composition of claim 1 , wherein the at least one nucleic acid is complexed to the cationic lipids to form a nucleic acid-lipid nanoparticle complex.
9. The composition of claim 1 , wherein the lipid nanoparticles are characterized as having a z-average diameter particle size measurement of 40 nm to 60 nm when measured using dynamic light scattering.
10. The composition of claim 1 , wherein the surface further comprises a hydrophobic surfactant and a hydrophilic surfactant.
11. The composition of claim 10 , wherein the hydrophobic surfactant is selected from the group consisting of sorbitan monostearate, sorbitan monooleate, and sorbitan trioleate.
12. The composition of claim 10 , wherein the hydrophilic surfactant comprises polyethylene oxide.
13. The composition of claim 12 , wherein the polyethylene oxide comprises polyoxyethylene sorbitan ester.
14. The composition of claim 10 , wherein the hydrophilic surfactant comprises polysorbate.
15. The composition of claim 14 , wherein the polysorbate comprises polysorbate 80.
16. The composition of claim 1 , wherein the liquid oil comprises squalene, sunflower oil, soybean oil, olive oil, grapeseed oil, capric/caprylic triglyceride, vitamin E, lauroyl polyoxylglyceride, or monoacylglycerol.
17. The composition of claim 1 , wherein the cationic lipid is 1,2-dioleoyloxy-3-(trimethylammonium) propane (DOTAP); 3b-[N-(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC Cholesterol); dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl-3-trimethylammoniumpropane (DMTAP); dipalmitoyl (C16:0)trimethyl ammonium propane (DPTAP); distearoyltrimethylammonium propane (DSTAP); N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA); N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA); or 1, r-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl) (2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl) azanediyl)bis(dodecan-2-ol) (C 12-200).
18. The composition of claim 1 , wherein the hydrophobic core further comprises a solid inorganic nanoparticle.
19. The composition of claim 18 , wherein the solid inorganic nanoparticle is selected from the group consisting of metal salts, metal oxides, metal hydroxides, and metal phosphates.
20. The composition of claim 18 , wherein the solid inorganic nanoparticle comprises iron oxide.
21. The composition of claim 20 , wherein the iron oxide is magnetite (Fe 3 O 4 ), maghemite (y-Fe 2 O 3 ), wüstite (FeO), hematite (a-Fe 2 O 3 ), or any combination thereof.
22. The composition of claim 1 , wherein the surface further comprises sorbitan monostearate and polysorbate 80, wherein the liquid oil is squalene, and wherein the cationic lipid is DOTAP.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 24, 2024
From: KHANDHAR, AMIT; REED, STEVEN; DUTHIE, MALCOLM; ERASMUS, JESSE; CARTER, DARRICK; BERUBE, BRYAN J.
To: HDT BIO CORP.
Reel/Frame 068672/0046 →
Continuity (9)
Continuation
PCTUS2021019103
· Feb 22, 2021
Provisional Application
63054754
· Jul 21, 2020
Provisional Application
62993307
· Mar 23, 2020
References Cited (211)
US 7045335B2
· Smith
· 2006
[cited by applicant]
US 7425337B2
· Smith
· 2008
[cited by applicant]
US 8709441B2
· Rayner
· 2014
[cited by applicant]
US 8734832B2
· O'Hagan et al.
· 2014
[cited by applicant]
US 8853179B2
· Mauro
· 2014
[cited by applicant]
US 9295646B2
· Kline
· 2016
[cited by applicant]
US 9555136B2
· Khandhar et al.
· 2017
[cited by applicant]
US 9655845B2
· Brito
· 2017
[cited by applicant]
US 20090252721A1
· Buschmann
· 2009
[cited by applicant]
US 20160000886A1
· Parker
· 2016
[cited by applicant]
US 20160201067A1
· Ataullakhanov
· 2016
[cited by applicant]
US 20180153848A1
· Chen
· 2018
[cited by applicant]
US 20180207295A1
· Fotin-Mleczek
· 2018
[cited by applicant]
US 20180311336A1
· Ciaramella
· 2018
[cited by applicant]
US 20190015501A1
· Ciaramella
· 2019
[cited by applicant]
US 20190274968A1
· Weissman
· 2019
[cited by applicant]
US 20190382450A1
· Belov
· 2019
[cited by applicant]
US 20200069599A1
· Smith
· 2020
[cited by applicant]
US 20210128583A1
· Zhang
· 2021
[cited by applicant]
US 20210283242A1
· Hutchins
· 2021
[cited by applicant]
US 20230310569A1
· Voigt
· 2023
[cited by applicant]
WO 2001021810A1
· 2001
[cited by applicant]
WO 2002080982A2
· 2002
[cited by applicant]
WO 2005107760A1
· 2005
[cited by applicant]
WO 2007024826A2
· 2007
[cited by applicant]
WO 2008124647A2
· 2008
[cited by applicant]
WO 2008153541A1
· 2008
[cited by applicant]
WO WO2009049083
· 2009
[cited by applicant]
WO 2010141861A1
· 2010
[cited by applicant]
WO WO2011156761
· 2011
[cited by applicant]
WO 2014042780A1
· 2014
[cited by applicant]
WO 2015103167A2
· 2015
[cited by applicant]
WO 2017200852A1
· 2017
[cited by applicant]
WO 2017200957A1
· 2017
[cited by applicant]
WO 2017205225A2
· 2017
[cited by applicant]
WO 2017210364A1
· 2017
[cited by applicant]
WO 2017218704A1
· 2017
[cited by applicant]
WO WO2018022957
· 2018
[cited by applicant]
WO 2018044028
· 2018
[cited by applicant]
WO 2018053294A1
· 2018
[cited by applicant]
WO WO2018147710
· 2018
[cited by applicant]
WO 2018232257
· 2018
[cited by applicant]
WO WO20182322257
· 2018
[cited by applicant]
WO WO2019152884
· 2019
[cited by applicant]
WO 2020132279A1
· 2020
[cited by applicant]
WO 2020243115
· 2020
[cited by applicant]
WO 2020254804A1
· 2020
[cited by applicant]
WO 2021021605A1
· 2021
[cited by applicant]
WO 2021076630A1
· 2021
[cited by applicant]
WO WO2021067480
· 2021
[cited by applicant]
WO WO2021072112
· 2021
[cited by applicant]
WO WO2021163536
· 2021
[cited by applicant]
WO 2021178886A1
· 2021
[cited by applicant]
WO 2021183564A1
· 2021
[cited by applicant]
WO 2021194672A1
· 2021
[cited by applicant]
WO WO2021194672
· 2021
[cited by applicant]
WO 2021210686A1
· 2021
[cited by applicant]
WO WO2022051022
· 2022
[cited by applicant]
WO 2022136952A1
· 2022
[cited by applicant]
WO 2022217079A1
· 2022
[cited by applicant]
WO 2023286076A1
· 2023
[cited by applicant]
WO 2023026301A1
· 2023
[cited by applicant]
WO 2023049636A1
· 2023
[cited by applicant]
WO 2023049636A2
· 2023
[cited by applicant]
WO 2023056202A2
· 2023
[cited by applicant]
Agnihothram, S., et al., “Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform” J Virol. May 14, 2018;92(11):e00027-18. doi: 10.1128/JVI.00027-18.
[cited by applicant]
Anderluzzi, G., et al., “Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines” Vaccines (Basel). May 8, 2020;8(2):212. doi: 10.3390/vaccines8020212.
[cited by applicant]
Bazhan, S., et al., “Immunogenicity and Protective Efficacy of Influenza A DNA Vaccines Encoding Artificial Antigens Based on Conservative Hemagglutinin Stem Region and M2 Protein in Mice.” Vaccines vol. 8,3 448. Aug. 9…
[cited by applicant]
Boettler, T., et al., “SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis” J Hepatol. Sep. 2022;77(3):653-659. doi: 10.1016/j.jhep.2022.03.040.
[cited by applicant]
Brito, L.A., et al., “A Cationic Nanoemulsion for the Delivery of Next-Generation RNA Vaccines” Mol Ther. 2014;22(12):2118-2129. doi:10.1038/mt.2014.133.
[cited by applicant]
Chiu, C.Y.H., et al., “Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria” Front Microbiol. Jun. 30, 2014;5:314. doi: 10.3389/fmicb.2014.00314.
[cited by applicant]
Deo, S., et al. “Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies.” Biochemical and Biophysical Research Communications 680 (2023): 108-118.
[cited by applicant]
Du, L., et al., “The Spike Protein of SARS-CoV—A Target for Vaccine and Therapeutic Development”, Nat Rev Microbiol 7, 226-236 (2009). https://doi.org/10.1038/nrmicro2090.
[cited by applicant]
Duerrwald, R., et al., “Influenza A virus (A/swine/Bueren/5439/2006(H3N2)) segment 4 hemagglutinin (HA) gene, complete cds”. Genbank entry (online). National Center for Biotechnology Information. URL: Https://www.ncbi.n…
[cited by applicant]
Erasmus, J.A., et al., “A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika”, Mol Ther. Oct. 3, 2018;26(10):2507-2522. doi: 10.1016/j.ymthe.2018.07.01…
[cited by applicant]
Felgner, Philip L., et al. “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.” Proceedings of the National Academy of Sciences 84.21 (1987): 7413-7417.
[cited by applicant]
Fleeton, M. N., et al., “Self-Replicative RNA Vaccines Elicit Protection Against Influenza A Virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus”, The Journal of Infectious Diseases, vol. 183, Issue 9…
[cited by applicant]
Fox, C.B., “Squalene emulsions for parenteral vaccine and drug delivery” Molecules. Sep. 1, 2009;14(9):3286-312. doi: 10.3390/molecules14093286.
[cited by applicant]
Gao, Y., et al., “Structure of the RNA-dependent RNA polymerase from COVID-19 virus” Science. May 15, 2020;368(6492):779-782. doi: 10.1126/science.abb7498.
[cited by applicant]
Gehardt, Alana, et al., “A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery” Mol Ther Methods Clin Dev. Jun. 9, 2022;25:205-214. doi: 10.1016/j.omtm.2022.03.009.
[cited by applicant]
Hatmal, M.M., et al., “Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2” Cells Dec. 8, 2020;9(12):2638. doi: 10.3390/cells9122638.
[cited by applicant]
Hawman, D. W. et al., “SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern” bioRxiv [Prepr…
[cited by applicant]
Heinz, F.X., and Stiasny, K., “Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action” NPJ Vaccines. Aug. 16, 2021;6(1):104. doi: 10.1038/s41541-021-00369-6.
[cited by applicant]
Huang, H.C., et al., “Formulation of novel lipid-coated magnetic nanoparticles as the probe for in vivo imaging” J Biomed Sci. Sep. 21, 2009;16(1):86. doi: 10.1186/1423-0127-16-86.
[cited by applicant]
Huang, Y., et al., “Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19” Acta Pharmacol Sin 41, 1141-1149 (2020). https://doi.org/10.1038/s41401-020-0485-4.
[cited by applicant]
International Search Report issued Jun. 6, 2022 in PCT/US2022/13513.
[cited by applicant]
International Search Report issued Jun. 13, 2024 in PCT/US2024/010326.
[cited by applicant]
International Search Report issued Jun. 8, 2022 in PCT/US2022/013516.
[cited by applicant]
International Search Report issued Jun. 14, 2022 in PCT/US2022/13508.
[cited by applicant]
International Search Report issued in PCT/US2023/060225 dated Jul. 28, 2023.
[cited by applicant]
International Search Report issued Jun. 29, 2023 in PCT/US2022/076787.
[cited by applicant]
International Search Report issued Jun. 6, 2022 in PCT/US2022/013513.
[cited by applicant]
International Search Report issued Jun. 7, 2023 in PCT/US2022/076304.
[cited by applicant]
Kautz, T. F., et al., “Low-fidelity Venezuelan equine encephalitis virus polymerase mutants to improve live-attenuated vaccine safety and efficacy” Virus Evol.:4(1); pp. 1-14, Mar. 6, 2018;. doi: 10.1093/ve/vey004.
[cited by applicant]
Kimuira, T, et al., “A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation”, Molecular Therapy (2023), doi: https://doi.org/10.1016/…
[cited by applicant]
Kwon, S.M., et al., “In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier” J Control Release. May 22, 2008;128(1):89-97. doi: 10.1016/j.jconrel.200…
[cited by applicant]
Marcus, M., et al., “Iron oxide nanoparticles for neuronal cell applications: uptake study and magnetic manipulations”, J Nanobiotechnology, vol. 14, Issue 37, May 2016, https://doi.org/10.1186/s12951-016-0190-0.
[cited by applicant]
Maruggi, G., et al., “A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models” Mol Ther. Jan. 3, 2022:S1525-0016(22)00001-6. doi: 10.1016/j.ymthe.2022.01.001.
[cited by applicant]
Min, J. W., et al., “Hemagglutinin (Influenza A virus (A/Aichi/2/1968(H3N2))]”. Genbank entry (online). National Center for Biotechnology Information. Retrieved From the Internet. URL: https://www.ncbi.nlm.nih.gov/prote…
[cited by applicant]
Pardi, N., et al., “mRNA vaccines—a new era in vaccinology” Nat Rev Drug Discov. Apr. 2018;17(4):261-279. doi:10.1038/nrd.2017.243. Epub Jan. 12, 2018. PMID: 29326426.
[cited by applicant]
Pin, Elisa, et al. “Identification of a Novel Autoimmune Peptide Epitope of Prostein in Prostate Cancer.” Journal of Proteome Research 16.1 (2017): 204-216.
[cited by applicant]
Roeffen, W., et al., “Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP. 10C chimeric protein formulated in different adjuvants” Malar J 14, 443 (2015). https://doi.org/10.1186/s12936-015-0972-…
[cited by applicant]
Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein, Sponsor: HDT Bio, posted Nov. 24, 2021ClinicalTrials.gov Identifier: NCT05132907 found at https://clinicaltrials.gov/ct2/show/record/NCT…
[cited by applicant]
Schoenmaker, L., et al. “mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.” International journal of pharmaceutics vol. 601 (2021): 120586. doi:10.1016/j.ijpharm.2021.120586.
[cited by applicant]
Shu, B., et al., “Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation”, Proc Natl Acad Sci USA; 113(28):E4005-14, Jun. 23, 2016 doi: 10.1073/pnas.1602591113.
[cited by applicant]
Singh, K., et al., “Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial” NPJ Vaccines. Sep. 28, 2018;3:48. doi: 10.1038/s41541-018-0083-3.
[cited by applicant]
Starmans, L.W.E., et al., “Iron oxide nanoparticle-micelles (ION-micelles) for sensitive (molecular) magnetic particle imaging and magnetic resonance imaging” PLoS One. 2013;8(2):e57335. doi: 10.1371/journal.pone.005733…
[cited by applicant]
Stokes, A., et al., “Nonclinical safety assessment of repeated administration and biodistribution of a novel rabies self-amplifying mRNA vaccine in rats” Regul Toxicol Pharmacol. Jun. 2020;113:104648. doi: 10.1016/j.yrt…
[cited by applicant]
Teixeira, T. et al., “Cationic nanoemulsions as nucleic acids delivery systems” Int J Pharm. Dec. 20, 2017;534(1-2):356-367. doi: 10.1016/j.ijpharm.2017.10.030.
[cited by applicant]
Tregoning, J. S., et al., “Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines” Mol Ther Nucleic Acids. Dec. 5, 2022;31:29-42. doi: 10.1016/j.omtn.2022.11.024.
[cited by applicant]
Tregoning, J.S.. “LION: Taming RNA vaccine inflammation” Mol Ther. Aug. 3, 2023:S1525-0016(23)00386-6. doi: 10.1016/j.ymthe.2023.07.006.
[cited by applicant]
Valdivia, L, et al., Solid Lipid Particles for Lung Metastasis Treatment. Pharmaceutics. 2021; 13(1):93. Published Jan. 13, 2021. doi:10.3390/pharmaceutics13010093.
[cited by applicant]
Voigt, E.A., et al., “A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability” npj Vaccines 7, 136 (2022). https://doi.org/10.1038/s41541-022-00549-y.
[cited by applicant]
Walton, T.E., et al., “Experimental infection of horses with an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83)” Infect Immun. May 1972;5(5):750-6. doi: 10.1128/iai.5.5.750-756.1972.
[cited by applicant]
Wu, F., et al., “Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome” GenBank: MN908947.3, VRL Mar. 18, 2020, available at https://www.ncbi.nlm.nih.gov/nuccore/MN908947.
[cited by applicant]
“Gennova's mRNA vaccine to come in powder form; will stay stable at 2-8 ° C.” Business Standard. Sep. 13, 2021 02:56 IST.
[cited by applicant]
Brinckerhoff, L. H., et al., “Melanoma vaccines” Current Opinion in Oncology: Mar. 2000—vol. 12—Issue 2—p. 163-173.
[cited by applicant]
Brocato, R. L., et al., Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters. NPJ Vaccines 6, 16 (2021). https://doi.org/10.1038/s41541-020-00279-z.
[cited by applicant]
Brown, C. M., et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings—Barnstable County, Massachusetts, Jul. 2021. MMWR Morb Mortal Wkly Rep …
[cited by applicant]
Corbett, K. S., et al., “Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates” N Engl J Med. Oct. 15, 2020;383(16):1544-1555. doi: 10.1056/NEJMoa2024671.
[cited by applicant]
Corman, V. C., et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3), https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
[cited by applicant]
CustomBiotech Online Development Exchange (CODE), Beyond COVID: The Future of mRNA technology, Webinar held Thursday, Nov. 11, 2021, https://dianews.roche.com/CustomBiotech-Webinar-2021.html.
[cited by applicant]
Edara, V., et al., Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B. 1.617 Variants. N Engl J Med. Aug. 12, 2021;385(7):664-666. doi: 10.1056/NEJMc2107799. Epub Jul. 7, 2021. PMID: 34233…
[cited by applicant]
Erasmus, J. H., A Nanostructured Lipid Carrier for Delivery of Replicating Viral RNA Provides Single, Low-Dose Protection against Zika, Molecular Therapy, vol. 26, No. 10. pp. 2507-2522.
[cited by applicant]
Erasmus, J. H., et al., “An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates” Science Translational Medicine, Aug. 5, 2020, vol. 12, Iss…
[cited by applicant]
Erasmus, J.H. et al., “Single-dose Replicating RNA Vaccine Induces Neutralizing Antibodies Against SARS-CoV-2 in Nonhuman Primates”, bioRxiv, 28 pages.
[cited by applicant]
Erasmus, J.H., “An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 Neutralizing Antibody and T-cell Responses in Mice and Nonhuman Primates”, Science Translational Medicine, vol. 12, No. 555.
[cited by applicant]
Erasmus, J.H., et al., Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection. Mol Ther—Methods Clin Dev. 2020;18:402-414. PMID: 32695842.
[cited by applicant]
File No: BIO/CT/20/000182, CT No. CT—Feb. 2021 Government of India Directorate General of Health Services Central Drugs Standard Control Organization (Biological Division), Form CT-06 Permission to Conduct Clinical Tria…
[cited by applicant]
File No: BIO/CT/21/00,105, CT No. CT-28/2021 Government of India Directorate General of Health Services Central Drugs Standard Control Organization (Biological Division), Form CT-06 Permission to Conduct Clinical Trial …
[cited by applicant]
Fischer, Robert J., et al. “ChAdOx1 nCOV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.” bioRxiv : the preprint server for biology 2021.03.11.435000. Jun. 30, 2021, doi:10.1101/2021.03.11.…
[cited by applicant]
Geall, Andrew J., et al. “Nonviral delivery of self-amplifying RNA vaccines.” PNAS. vol 109. No 36, pp. 14604-14609 (2012).
[cited by applicant]
Gilchuk, P., et al., “Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics” Nat Biomed Eng. 2020;4(11):1030-1043. PMID: 32747832.
[cited by applicant]
Hörner , C., et al., A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine, Proceedings of the National Academy of Sciences Dec. 2020, 117 (51) 32657-32666; DOI: 10.1073/pnas.2014468117.
[cited by applicant]
Hou, X., et al., Lipid nanoparticles for mRNA delivery. Nat Rev Mater (2021). https://doi.org/10.1038/s41578-021-00358-0.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2021/019103 issued Sep. 30, 2021.
[cited by applicant]
Jain, T.K., et al., Iron Oxide Nanoparticles for Sustained Delivery of Anticancer Agents, Molecular Pharmaceutics, American Chemical Society, 2 (3), 194-205, 2005.
[cited by applicant]
Kalnin, K.V., et al., Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. npj Vaccines 6, 61 (2021). https://doi.org/10.1038/s41541-021-00324-5.
[cited by applicant]
Kurup, D. et al., Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model, PLOS Pathogens 17(3): e1009383. https://doi.org/10.1371/journal.ppat.1009383.
[cited by applicant]
Li, Q. et al., “A Review of the Structure, Preparation, and Application of NLCs, PNPs and PLNs”, Nanomaterials, vol. 7, No. 6, p. 1-25.
[cited by applicant]
Limbach, P A et al. “Summary: the modified nucleosides of RNA.” Nucleic acids research vol. 22, 12 (1994): 2183-96. doi:10.1093/nar/22.12.2183.
[cited by applicant]
Lopez Bernal, J, et al., Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. Aug. 12, 2021;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub Jul. 21, 2021. PMID: 34289274; PMCID: PMC83…
[cited by applicant]
Machado, B.A.S., et al., The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Vaccines (Basel). Nov. 17, 2021;9(11):1345. doi: 10.3390/vaccines9111345. PMID: 34835276; PMCID: PMC8623509.
[cited by applicant]
McKay, P. F., et al., Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun. Jul. 9, 2020;11(1):3523. doi: 10.1038/s41467-020-17409-9. PMID: 32…
[cited by applicant]
Mercado, N.B., et al., “Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques” Nature. Oct. 2020;586(7830):583-588. doi: 10.1038/s41586-020-2607-z. Epub Jul. 30, 2020. Erratum in: Nature. Feb. 2021;590…
[cited by applicant]
Meyer, B., et al., Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential. Nat Commun. Sep. 21, 2021;12(1):5553. doi: 10.1038/s41467-021-25…
[cited by applicant]
Mohandas, S., et al., Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model. iScience. Feb. 19, 2021;24(2):102054. doi: 10.1016/j.isci.2021.…
[cited by applicant]
Planas, D., et al., Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. Aug. 2021;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub Jul. 8, 2021. PMID: 34237773.
[cited by applicant]
Rauch, S, et al., mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines. Apr. 16, 2021;6(1):57. doi: 10.1038/s41541-021-0031…
[cited by applicant]
Sheikh, A, et al., SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. Jun. 26, 2021;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1. Epub Jun. 14, 202…
[cited by applicant]
Shen, X, et al., SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. Apr. 14, 2021;29(4):529-539.e3. doi: 10.1016/j.chom.2021.03.002. Epub Mar. 5…
[cited by applicant]
Szurgot, I., et al., DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice. 2021 Scientific Reports. 11. 10.1038/s41598-021-82498-5.
[cited by applicant]
Van Der Lubbe, J. E. M., et al., Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. NPJ Vaccines. Mar. 19, 2021;6(1):39. doi: 10.1038/s41541-021-00301-y.…
[cited by applicant]
Van Doremalen, N., et al. Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates. bioRxiv [Preprint]. Jul. 7, 2021:Jul. 7, 2021.451505. doi: 10.1101/2021.07.07.451505. Update…
[cited by applicant]
Van Doremalen, N., et al., ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. Oct. 2020;586(7830):578-582. doi: 10.1038/s41586-020-2608-y. Epub Jul. 30, 2020. Erratum in: Nature. Feb. 2021…
[cited by applicant]
V'Kovski, P, et al., “Coronavirus biology and replication: implications for SARS-CoV-2”. Nature Reviews. (Mar. 2021). Microbiology. 19 (3): 155-170. doi:10.1038/s41579-020-00468-6. PMC 7592455. PMID 33116300.
[cited by applicant]
Wang, P., et al., Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. May 2021;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub Mar. 8, 2021. PMID: 33684923.
[cited by applicant]
Wang, Z., et al., Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. Jul. 2021;595(7867):426-431. doi: 10.1038/s41586-021-03696-9. Epub Jun. 14, 2021. PMID: 34126625; PMCID: PMC…
[cited by applicant]
Wu, C, et al. “Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods,” Acta Pharmaceutica Sinica (May 2020). B. 10 (5): 766-788. doi:10.1016/j.apsb.2020.02.008. PMC 710…
[cited by applicant]
Yinda, C. K., et al., Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerg Microbes Infect. Dec. 2021;10(1):1284-1292. doi:…
[cited by applicant]
Yu, Jingyou et al. “DNA vaccine protection against SARS-CoV-2 in rhesus macaques.” Science (New York, N.Y.) vol. 369,6505 (2020): 806-811. doi:10.1126/science.abc6284.
[cited by applicant]
Zhang, Y., et al., A second functional furin site in the SARS-CoV-2 spike protein. Emerg Microbes Infect. Dec. 3, 2021:1-35. doi: 10.1080/22221751.2021.2014284. Epub ahead of print. PMID: 34856891.
[cited by applicant]
Zhou, D., et al., Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. Apr. 29, 2021;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub Feb. 23, 2021. PMID: 33730597; PMC…
[cited by applicant]
Zost, S.J., et al., Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020;26(9):1422-1427. PMID: 32651581.
[cited by applicant]
Gerhardt, Alana, et al. “A thermostable, flexible RNA vaccine delivery platform for pandemic response.” bioRxiv (2021): Feb. 2021.
[cited by applicant]
Enterovirus D68 strain US/MO/14-18947, partial genome, 2014, www.ncbi.nlm.nih.gov/nuccore/KM851225, accessed Mar. 5, 2025. (Year: 2014).
[cited by applicant]
Hubert, B. “Reverse Engineering the source code of the BioNTech/Pfizer SARS-CoV-2 vaccine.” published Feb. 23, 2021, 15 pages and cover page, https://web.archive.org/web/20210223123219/https://berthub.com.eu/articles/po…
[cited by applicant]
Kulkarni, Jayesh A., et al. “Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles.” Nanoscale 9.36 (2017): 13600-13609.
[cited by applicant]
Malhi, Harman, et al. “Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.” Cell Reports Medicine 3.6 (2022).
[cited by applicant]
Manzano, Mark, et al. “Identification of cis-acting elements in the 3′ -untranslated region of the dengue virus type 2 RNA that modulate translation and replication.” Journal of Biological Chemistry 286.25 (2011): 22521…
[cited by applicant]
Nakamura, Takashi, et al. “The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution.” Molecular pharmaceutics 17.3 (2020): 944-953.
[cited by applicant]
Vargas, Kevin M., and Young-Seok Shon. “Hybrid lipid-nanoparticle complexes for biomedical applications.” Journal of Materials Chemistry B 7.5 (2019): 695-708.
[cited by applicant]
Venezuelan equine encephalitis virus strain TC-83, complete genome, 2004, www.ncbi.nlm.nih.gov/nuccore/323714, accessed Mar. 5, 2025 (Year: 2004).
[cited by applicant]
Wang et al., Enterovirus D68 isolate DZH-ZJUC, complete genome, Pub. Med. Sequence submission on Sep. 17, 2019. Https://www.ncbi.nlm.nih.gov/nuccore/MK614087.1/ (printed Oct. 17, 2024).
[cited by applicant]
Xiong, Cheng, et al. “Sindbis virus: an efficient, broad host range vector for gene expression in animal cells.” Science 243.4895 (1989): 1188-1191.
[cited by applicant]
Yan, Qin, et al. “Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges.” Vaccine 34.35 (2016): 4196-4204.
[cited by applicant]
Yates, M. in Microbiology of Waterborne Diseased, 2nd ed. In Enterovirus; Enterovirus—an overview, ScienceDirect Topics, 2014, 2 pages.
[cited by applicant]
Zhang, Chao, et al. “Enterovirus D68 virus-like particles expressed in Pichia pastoris potently induce neutralizing antibody responses and confer protection against lethal viral infection in mice.” Emerging Microbes & I…
[cited by applicant]
Ziegler, E., et al. “Foot- and-mouth disease virus Lb proteinase can stimulate rhinovirus and enterovirus IRES-driven translation and cleave several proteins of cellular and viral origin.” Journal of Virology 69.6 (1995…
[cited by applicant]